Paricalcitol and Extended-Release Calcifediol for Treatment of Secondary Hyperparathyroidism in Non-Dialysis Chronic Kidney Disease: Results From a Network Meta-Analysis
Authors' conclusion
This network meta-analysis showed that ERC is comparable in lowering PTH levels vs PCT. ERC displayed avoidance of potentially clinically relevant increases in serum calcium, offering an effective and well-tolerated treatment option for the management of SHPT in patients with ND-CKD.
Study context
- Population
- Patients with non-dialysis CKD (ND-CKD) and secondary hyperparathyroidism (SHPT)
- Participants
- 1,426 patients9 randomized control trials (RCTs)
- Comparison
- Extended-release calcifediol vs paricalcitol
- Outcome
- PTH reduction
Methodological detailsfrequentist, random effects, GRADE quality assessment, no head-to-head trials, PubMed search for RCTs
- Frequentist
- Random effects
- GRADE quality assessment
- No head-to-head trials
- PubMed search for RCTs
Pooled result
As reported in the abstract
- No statistically significant differences in parathyroid hormone (PTH) reduction between paricalcitol (PCT) and ERC
- 2 overlapping networks
Further pooled results
- No differences in effects on phosphate
Safety
| Outcome | Increase (mg/dL) (95% CI) |
|---|---|
| Calcium increase | 0.2 (−0.37 to −0.05) |
- Calcium increase: statistically significant increase with PCT; estimate outside its printed CI
Original publication
Paricalcitol and Extended-Release Calcifediol for Treatment of Secondary Hyperparathyroidism in Non-Dialysis Chronic Kidney Disease: Results From a Network Meta-Analysis. J Clin Endocrinol Metab. Published 26 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →